Trial · NCT05701189
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Guillain-Barre Syndrome Disability Scale (GBS-DS) | Week 4 | Scoring system that assesses the functional status of GBS subjects. Scores range from 0 to 6, with higher scores indicating a worse outcome. |
| Primary | Number and seriousness in adverse events in the studied population | Through study completion, an average of 3 years | Safety monitoring |
| Secondary | Guillain-Barre Syndrome Disability Scale (GBS-DS) | 12 and 24 weeks | Scoring system that assesses the functional status of GBS subjects. Scores range from 0 to 6, with higher scores indicating a worse outcome. |
| Secondary | MRC Sum Score | 12 and 24 weeks | Quantifies strength, with a higher score indicating more strength. |
| Secondary | Inflammatory Rasch-Built Overall Disability Scale (I-RODS) | 4, 8, 12, and 24 weeks | Functional outcome assessment. Scores range from 0 to 48, with higher scores indicating a better outcome. |
| Secondary | Number of Days on Respirator | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Number of days in an intensive care unit | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Number of days to hospital discharge | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Mortality | 4, 8, 12, and 24 weeks | Change in vital status |
| Secondary | Percentage of patients with secondary deterioration due to treatment-related fluctuations (TRF) | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Adverse Events | 4, 8, 12, and 24 weeks | occurrence of adverse events |
| Other | Study effect of Efgartigimod on IgG levels | change from baseline to 4 weeks and 24 weeks | Blood sample to analyze change in IgG levels |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05701189/registered